Table 2.
Drugs decreasing macrophage and mast cell infiltration and activation.
Reference | Drug | Effect | Endometriosis Source | Experimental Model |
---|---|---|---|---|
Haber et al., 2009 [102] | Liposomal bisphosphonate | Decline in endometriotic lesion volume | Rodent (rat) | Autotransplantation rat model |
less macrophage infiltration | ||||
Foster et al., 2019 [96] | Liposomal clodronate | Less macrophage infiltration | Human (pelvic endometriotic lesions) | In vitro culture; xenotransplantation murine model |
Decrease in IGF-1 expression | ||||
Linsitinib | Attenuation of hyperalgesia | |||
Ihara et al., 2004 [103] | Leukotriene receptor antagonists | Lower stromal proliferation rates | Rodent (rat) | Autotransplantation rat model |
Decline in mast cell infiltration and activation | ||||
Guney et al., 2008 [104] | Melatonin | Decline in endometriotic lesion volume | Rodent (rat) | Autotransplantation rat model |
Increased SOD and CAT activity | ||||
Lower MDA levels | ||||
Yildirim et al., 2009 [105] | Melatonin | Decline in endometriotic lesion volume | Rodent (rat) | Autotransplantation rat model |
Increased SOD and CAT activity | ||||
Schwertner et al., 2013 [106] | Melatonin | Alleviation of chronic pain | Human (pelvic endometriotic lesions) | Endometriosis patients with chronic pain |
Improvement in dysmenorrhea and dyspareunia | ||||
Improvement in dyschezia and dysuria | ||||
Lower BDNF levels | ||||
Iuvone et al., 2016 [107] | PEA | Decrease in mast cell numbers | Rodent (rat) | Autotransplantation rat model |
Decline in endometriotic lesion volume | ||||
Idraccolo et al., 2017 [108] | PEA + polydatin | Alleviation of chronic pain | Human (pelvic endometriotic lesions) | Endometriosis patients with chronic pain |
Improvement in dysmenorrhea and dyspareunia | ||||
No improvement in dyschezia |
PEA, ultramicronized palmitoylethanolamide; IGF-1, insulin growth factor 1; SOD, superoxide dismutase; CAT, catalase; MDA, malondialdehyde; BDNF, brain-derived neurotrophic factor.